NCT04842435 is a Phase 2, PHASE3 clinical trial of COVID-globulin in COVID-19, sponsored by Microgen.

Who is sponsoring NCT04842435?

NCT04842435 is sponsored by Microgen.

What drugs are being tested in NCT04842435?

Interventions in NCT04842435: COVID-globulin, Placebo.

Is NCT04842435 still recruiting?

NCT04842435 is currently status unknown. Last updated 14 May 2021.

Last reviewed 2021-05-14 · How we verify

NCT04842435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study in the Treatment of Patients With Moderate Course of COVID-19

Status unknown Phase 2, PHASE3 Last updated 14 May 2021

What this trial tests

Phase 2, PHASE3 trial testing COVID-globulin in COVID-19 in 376 participants. Status unknown.

Timeline

12 April 2021

Primary endpoint
30 September 2021

5 October 2021

Quick facts

Lead sponsor	Microgen
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	376
Start date	12 April 2021
Primary completion	30 September 2021
Estimated completion	5 October 2021
Sites	21 locations across Russia

Drugs / interventions tested

COVID-globulin — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Microgen — full company profile →

Who can join

Adults 18 to 65, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of safety, efficacy and pharmacokinetics, dose selection

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04842435 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Microgen
Last refreshed: 14 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04842435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing